- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02364544
Improving Care and Reducing Cost Study (ICRC)
The Improving Care and Reducing Cost (ICRC) Program
Study Overview
Status
Conditions
Detailed Description
The goal of the Improving Care and Reducing Cost (ICRC) Program, is to improve disease management and the overall process of care in treating the chronic illness schizophrenia in order to reduce ER visits and hospital days while providing better care, better health and increased patient satisfaction. This will be done by fostering innovation in the use of technology and by training and deploying a new cadre of personnel in the behavioral health field: Mental Health/Health Technology (MH/HT) Case Managers. The specific treatments we propose to use are evidence based, but their dissemination has been limited because of lack of trained personnel and cost. The model we propose, the Health Technology Program (HTP), will address these problems through use of the web and mobile phone based training and interventions.
The components of the HTP program that are being tested in the pilot program include: 1) evidence-based pharmacological treatment facilitated by a web-based prescriber decision support system-Prescriber Decision Assistant (PDA) 2) brief, in-person, relapse prevention counseling with supplemental web-based learning modules, 3) a daily support website that offers web- and phone-based resources to support persons with schizophrenia and their family members or others. The resources include a patient and family Psycho-Education Treatment program, which includes electronic peer groups facilitated by mental health professionals, providing medication reminders via web and phone, and conducting monitoring of early warning signs of relapse via web and phone 4) an interactive smart phone text-messaging application to support medication adherence, facilitate coping with symptoms and improve daily functioning in individuals with schizophrenia 5) a web-based, self-administered cognitive-behavioral therapy (CBT) program for the management of hallucinations. All patients will be provided with pharmacological treatment (PDA), brief in-person relapse prevention counseling, and an Android mobile phone. The other program components will be provided to patients using a shared decision-making approach to assess need and preference.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Ft Lauderdale, Florida, United States, 33319
- Henderson Mental Health Center
-
-
Indiana
-
Lawrenceburg, Indiana, United States, 47025
- Community Mental Health Center, Inc.
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Cherry Street
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- UMKC School of Pharmacy
-
Springfield, Missouri, United States, 65802
- Burrell Behavioral Health
-
-
New Hampshire
-
Manchester, New Hampshire, United States, 03101
- The Mental Health Center of Greater Manchester
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- University of New Mexico Department of Psychiatry UNM Health Sciences Center
-
-
Oregon
-
Eugene, Oregon, United States, 97401
- PeaceHealth Oregon/Lane County Behavioral Health Services
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
• Age 18 to 60, (patients age 51-60 require review from the coordinating site)
Clinical diagnosis of:
- schizophrenia
- schizoaffective disorder
- psychosis NOS
- Has had two or more inpatient hospitalizations for treatment of a psychotic disorder
Currently in the hospital or up to 30 days of inpatient hospitalization for a psychotic disorder
o If patients are sent to a partial, or day hospital following an inpatient hospitalization, the 30 day window begins at the time of discharge from the day or partial hospital
- Any ethnicity
- Ability to participate in research assessments in English
- Ability to provide fully informed consent
Exclusion Criteria:
• Individuals who cannot understand what research participation entails, or correctly answer the questions about research participation that are part of the Study Information Review and provide fully informed consent will be excluded
- More than 30 days since discharge from a psychiatric hospitalization
- Any other serious medical condition that in the opinion of the investigator would seriously impair functioning making the patient unsuitable for the trial
- Patients who would likely find it burdensome and/or have difficulty sustaining the use of a laptop computer and /or smart phone due to issues of security, consistent connectivity or other factors.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Health Technology Program
The components of the treatment model include: 1) Prescriber Decision Assistant (PDA) 2) relapse prevention plan, 3) the daily support website 4) FOCUS, an interactive smart phone text-messaging application 5) a web-based, cognitive-behavioral therapy (CBT) program All patients will be provided with pharmacological treatment (PDA), brief in-person relapse prevention counseling, and an Android mobile phone. The other program components will be provided to patients using a shared decision-making approach to assess need and preference. |
brief, in-person, relapse prevention counseling with supplemental web-based learning modules,
web-based program for patients and families that provides psychoeducation about schizophrenia and its treatments to improve knowledge, increase problem-solving skills and offer social support through the use of web-based therapist facilitated sessions
A ten-session CBT programs, one to address voices and the other for paranoia.
The web-based programs incorporate the essential elements of CBT for psychosis such as normalizing behavior and offering behavioral coping strategies
an interactive smart phone text-messaging application to support medication adherence, facilitate coping with symptoms and improve daily functioning in individuals with schizophrenia
is a web-based prescriber decision support system that includes a brief patient-completed assessment describing symptoms and adverse events which prompts the prescriber to conduct a detailed clinical assessment.
Embedded in the program are decision supports for medication choices based on best evidence-based practices regarding symptoms, side effects, information from laboratory tests and history of prior treatment response
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Number of Hospitalization and Emergency Room Visits
Time Frame: Baseline, Month 1, Month2, Month 3, Month4, Month 5, and Month 6
|
Captures the number of hospital and ER visits each month
|
Baseline, Month 1, Month2, Month 3, Month4, Month 5, and Month 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Service Utilization Resource Form
Time Frame: Baseline, month 3, month 6
|
Captures services received in the last 30 days
|
Baseline, month 3, month 6
|
Change from Baseline Heinrich's Quality of Life Scale
Time Frame: Baseline and month 6
|
Baseline and month 6
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: John Kane, Northwell Health
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICRC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Relapse Prevention Plan
-
University of California, San FranciscoCompleted
-
University of WashingtonNational Institute on Drug Abuse (NIDA)CompletedSubstance Use DisordersUnited States
-
Chestnut Health SystemsRecruitingSubstance Use DisordersUnited States
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Conselho Nacional de...CompletedBenzodiazepine DependenceBrazil
-
3-C Institute for Social DevelopmentCompletedSubstance-Related DisordersUnited States
-
Loma Linda UniversityMarch of Dimes; American Academy of Pediatrics; Flight Attendant Medical Research...Completed
-
Alexandria UniversityCompleted
-
Villa Garda HospitalCompleted
-
Texas A&M UniversityMedical University of South Carolina; National Institute on Alcohol Abuse and...Not yet recruitingPosttraumatic Stress Disorder | Alcohol Use Disorder
-
University of Colorado, DenverNational Institute on Alcohol Abuse and Alcoholism (NIAAA); University of Colorado...Completed